| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.77% | 86.37% | 85.33% | 86.49% | 86.38% | 84.95% | 88.60% | 97.59% | 100.00% | — | — | — |
| Operating Margin | 13.51% | -7.87% | -15.43% | -75.68% | -83.93% | -168.09% | -427.50% | -1087.56% | -556.20% | -900.33% | — | — |
| EBITDA Margin | 15.00% | -5.35% | -12.48% | -71.39% | -78.30% | -161.04% | -419.68% | -1078.97% | -541.33% | -868.25% | — | — |
| Net Margin | 8.45% | -12.37% | -24.08% | -109.04% | -101.01% | -174.15% | -403.24% | -1016.58% | -545.95% | -869.63% | — | — |
| Current Ratio | 2.76 | 2.78 | 3.08 | 3.51 | 4.04 | 4.47 | 4.87 | 6.69 | 12.23 | 5.10 | 17.80 | 7.83 |
| Quick Ratio | 2.71 | 2.71 | 2.99 | 3.34 | 3.91 | 4.34 | 4.71 | 6.56 | 12.23 | 5.10 | 17.80 | 7.83 |
| Debt / Equity | — | — | — | — | 1.15 | 0.19 | — | — | — | — | — | — |
| ROE | 39.76% | -414.62% | 199.53% | 714.91% | -144.99% | -84.46% | -61.59% | -58.49% | -27.79% | -44.57% | -22.94% | -38.49% |
| ROA | 6.32% | -6.56% | -11.49% | -31.90% | -23.41% | -25.19% | -37.00% | -48.36% | -24.61% | -32.48% | -20.92% | -33.38% |
| Asset Turnover | 0.75 | 0.53 | 0.48 | 0.29 | 0.23 | 0.14 | 0.09 | 0.05 | 0.05 | 0.04 | — | — |
| Book Value / Share | 5.86 | 0.53 | -1.77 | -1.30 | 4.97 | 8.84 | 13.17 | 12.94 | 19.51 | 10.75 | — | — |
Alnylam Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing RNA interference (RNAi) therapeutics. This innovative gene silencing technology targets the root causes of diseases at the genetic level, offering potential treatments for rare and prevalent conditions across multiple therapeutic areas. The company specializes in creating transformational medicines that address unmet medical needs in sectors such as rare diseases, cardiometabolic disorders, and other genetic conditions. Alnylam Pharmaceuticals Inc advances a pipeline of investigational RNAi therapeutics designed for subcutaneous or intravenous administration, emphasizing precision medicine approaches. Its products and programs primarily serve patients worldwide through partnerships with healthcare providers and regulatory pathways. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals Inc plays a significant role in the biotechnology sector by pioneering RNAi as a novel modality for disease modification and management.